

Medical Policies



Policy Number: fep_2.04.151

Policy Name: Germline Variant Testing (Including Liquid Biopsy) for Targeted Treatment in Advanced Cancer

Policy Type: Medical Policy Subtype: Pathology/Laboratory

Effective Date: 10-01-2026

Review Date: 08-01-2027

Last Review Date: 08-25-2026

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Annual Effective Policy Date: October 1, 2026

Original Policy Date: March 2021

Related Policies:

- 2.04.02 - Germline Genetic Testing for Hereditary Breast/Ovarian Cancer Syndrome and Other High-Risk Cancers (BRCA1, BRCA2, PALB2)
- 2.04.115 - Comprehensive Genetic Profiling for Selecting Targeted Cancer Therapies
- 2.04.141 - Circulating Tumor DNA and Circulating Tumor Cells for Cancer Management (Liquid Biopsy)
- 2.04.36 - Assays of Genetic Expression in Tumor Tissue as a Technique to Determine Prognosis and Predict Therapeutic Response in Individuals With Breast Cancer
- 2.04.85 - BCR-ABL1 Testing in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia
- 5.01.12 - Trastuzumab
- 5.01.22 - Ado-Trastuzumab Emtansine (Trastuzumab-DM1) for Treatment of HER2-Positive Malignancies

Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Breast Cancer (BRCA1, BRCA2, PIK3CA, Ki-67, RET, BRAF, ESR1, NTRK)

DESCRIPTION

Multiple biomarkers are being evaluated to select treatment with an FDA-approved targeted treatments for patients with unresectable, recurrent, relapsed, refractory, advanced or metastatic cancer. These include tissue-based testing as well as circulating tumor DNA (known as liquid biopsy).

The objective of this evidence review is to examine whether genetic biomarker testing for BRCA1, BRCA2, PIK3CA, ESR1, BRAF, EGFR, EZH2, HER2, FOLR1, FLT3, CLDN18, FGFR3, PDGFRA, TP53, KRAS, NRAS, IDH1, IDH2, HLA, KIT, MET, homologous recombination deficiency (HDR), and homologous recombination repair (HRR) gene variants, ALK, ROS1, RET, FGFR2, PDGFR, NTRK, KMT2A, Philadelphia chromosome rearrangements or fusions, and other molecular

signatures, such as, PD-L1, MSI/MMR, and TMB status, in tumor tissue, or circulating tumor DNA improves the net health outcome in patients with unresectable, recurrent, relapsed, refractory, advanced or metastatic cancer who are considering targeted therapy (Table 1).

Table PG1. Gene Variants Found In DNA For Targeted Therapy

Biomarker	Indication
ALK rearrangements/fusions	NSCLC
ATM	Prostate
BRAF	Breast, NSCLC, metastatic CRC, Melanoma, Glioma, and ATC
BRCA1/2	Breast, Ovarian, Pancreatic, and Prostate
CLDN18	Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
EGFR	NSCLC, CRC,
ERBB2 (HER2)	Breast, NSCLC, Gastric and Gastroesophageal Cancer, and Biliary Tract Cancer (gallbladder adenocarcinoma, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma)
ESR1	Breast
EZH2	Follicular Lymphoma
FGFR2	Cholangiocarcinoma
FGFR3	Urothelial Cancer
FLT3 (ITD/TKD)	Acute Myelogenous Leukemia
FOLR1	Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
HER2	NSCLC and metastatic CRC
HLA	Uveal Melanoma
HRDa	Ovarian
HRR (BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D, and RAD54L)	Prostate
IDH1	Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Cholangiocarcinoma, Astrocytoma, Oligodendroglioma, and Glioma
IDH2	Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Astrocytoma, Oligodendroglioma, and Glioma
KIT	Aggressive Systemic Mastocytosis
KMT2A	Acute Myeloid Leukemia (AML)
KRAS	NSCLC and metastatic CRC
MET	NSCLC
MSI (MLH1, MSH2, MSH6, PMS1 and PMS2)/MMR (MLH1, MSH2, PMS2, and MSH6)	Solid tumors

Not MSI-H	Endometrial Carcinoma
NRAS	metastatic CRC
NTRK rearrangements/fusions	Breast, NSCLC, metastatic CRC, Ovarian, Prostate, Melanoma, Glioma, and other solid tumors
PDGFRA	Gastrointestinal Stromal Tumors
PDGFRB	Myelodysplastic Syndrome/Myeloproliferative Disease
PD-L1	Solid tumors
PIK3CA	Breast
RET rearrangements/fusions	Breast, NSCLC, metastatic CRC, Medullary Thyroid Cancer, Thyroid Cancer, and other solid tumors
ROS1 rearrangements/fusions	NSCLC
TMB	Solid tumors
TP53	B-cell Chronic Lymphocytic Leukemia
ATC: anaplastic thyroid cancer; CRC: colorectal cancer; HRD: homologous recombination deficiency; HRR: homologous recombination repair; NSCLC: non-small cell lung cancer; TMB: tumor mutational burden. a Genomic instability score	

Summary Of Evidence

For individuals with unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer who are being considered for targeted therapy with an FDA-approved drug consistent with the labeled indication, the evidence includes FDA-approved therapeutics with National Comprehensive Cancer Network (NCCN) recommendations of 2A or higher and was not extensively evaluated. The evidence includes the pivotal studies leading to the FDA and National Comprehensive Cancer Network (NCCN) recommendations.

Additional Information

Not applicable.

OBJECTIVE

The objective of this evidence review is to summarize the evidence and guidelines on genetic biomarker testing using tissue biopsy or circulating tumor DNA testing to select targeted treatment for individuals with unresectable, recurrent, relapsed, refractory, advanced, or metastatic cancer.

POLICY STATEMENT

Germline And Somatic Biomarker Testing (Including Liquid Biopsy) For Targeted Treatment In Breast Cancer (BRCA1, BRCA2, PIK3CA, Ki-67, RET, BRAF, ESR1, NTRK)

BRCA1 And BRCA2 Testing

Genetic testing for *BRCA1* or *BRCA2* germline variants may be considered **medically necessary** for all of the following:

- to predict treatment response to PARP inhibitors (eg, olaparib [Lynparza] and talazoparib [Talzenna]) for human epidermal receptor 2 (HER2)-negative metastatic and early stage, high-risk breast cancer (see Policy Guidelines).

Genetic testing of *BRCA1* or *BRCA2* germline or somatic variants in individuals with breast cancer for guiding therapy is considered **investigational** in all other situations.

PIK3CA Testing

PIK3CA testing may be considered **medically necessary** to predict treatment response to alpelisib (Piqray) in any of the following:

- individuals with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who have progressed on or after an endocrine-based regimen (see Policy Guidelines).

NOTE:

When tumor tissue is available, use of tissue for testing is preferred but is not required (see Circulating Tumor DNA Testing below).

PIK3CA testing of tissue in individuals with breast cancer is considered **investigational** in all other situations.

Ki-67 Testing

Ki-67 testing to predict treatment response to abemaciclib (Verzenio) in individuals with breast cancer is considered **investigational**.

RET Testing

RET testing to predict treatment response to selpercatinib (Retevmo) in individuals with breast cancer is considered **investigational**.

BRAF Testing

BRAF testing to predict treatment response to dabrafenib (Tafinlar) plus trametinib (Mekinist) in individuals with breast cancer is considered **investigational**.

Circulating Tumor DNA Testing (Liquid Biopsy)

PIK3CA testing using FoundationOne Liquid CDx may be considered **medically necessary** to predict treatment response to alpelisib (Piqray) in any of the following:

- individuals with hormone receptor-positive, HER2 negative advanced or metastatic breast cancer who have progressed on or after an endocrine-based regimen (see Policy Guidelines).

NOTE: When tumor tissue is available, use of tissue for testing is preferred but is not required.

ESR1 testing using Guardant360 CDx may be considered **medically necessary** to predict treatment response to elacestrant (Orserdu) in any of the following:

- individuals with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy (see Policy Guidelines).

Circulating tumor DNA testing in individuals with breast cancer is considered **investigational** in all other situations.

Circulating Tumor Cell Testing

Analysis of circulating tumor cells to select treatment in individuals with breast cancer is considered **investigational**.

NTRK Gene Fusion Testing

NTRK gene fusion testing may be considered **medically necessary** for any of the following:

- individuals with recurrent unresectable (local or regional) or stage IV breast cancer to select individuals for treatment with FDA-approved therapies

NTRK gene fusion testing in individuals with breast cancer is considered **investigational** in all other situations.

Other

NOTE: Testing for other variants may become available between policy updates.

Procedure Codes

0022U	0023U	0037U	0040U	0154U	0155U	0172U	0177U	0211U	0239U
0326U	0338U	0471U	0473U	0523U	0543U	81120	81121	81162	81163
81164	81165	81167	81191	81192	81193	81194	81206	81207	81210
81212	81215	81217	81235	81236	81237	81245	81246	81272	81273
81275	81276	81301	81307	81308	81309	81311	81314	81351	81352
81353	81370	81371	81372	81373	81374	81375	81376	81377	81378
81379	81380	81381	81382	81383	81400	81401	81402	81403	81404
81405	81406	81407	81408	81432	81445	81449	81450	81455	81456
81479**	88271	88275	88341*	88342*	88360*	88361*	88364*	88365*	88366*
88367	88368	88369	88374	88377	96041*	** (Unlisted Code)		*(Add on Code)	
0111U									

POLICY GUIDELINES

See U.S. Food and Drug Administration labels, clinical trials, and NCCN guidelines for specific population descriptions. Descriptions varied slightly across sources.

This policy does not address germline testing for inherited risk of developing cancer.

This policy does not address HER2 testing. Agents targeted against HER2 with approved companion diagnostic tests include monoclonal antibodies (margetuximab, pertuzumab, trastuzumab) and antibody-drug conjugates (ado-trastuzumab emtansine, fam-trastuzumab deruxtecan), which are not true targeted therapies. The use of ado-trastuzumab emtansine is addressed separately in evidence review 5.01.22.

For expanded panel testing, see evidence review 2.04.115.

Testing for individual genes (not gene panels) associated with FDA-approved therapeutics (i.e., as companion diagnostic tests) for therapies with National Comprehensive Cancer Network (NCCN) recommendations of 2A or higher are not subject to extensive evidence review. Note that while the FDA approval of companion diagnostic tests for genes might include tests that are conducted as panels, the FDA approval is for specific genes (such as driver mutations) and not for all of the genes on the test panel.

FDA approves tests in between policy review cycles. As such, newly approved tests might need to be considered per local Plan discretion. For guidance on testing criteria between policy updates, refer to the FDA's List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools) (<https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>) for an updated list of FDA-approved tumor markers and consult the most current version of NCCN management algorithms.

Genetic Counseling

Genetic counseling is primarily aimed at patients who are at risk for inherited disorders, and experts recommend formal genetic counseling in most cases when genetic testing for an inherited condition is considered. The interpretation of the results of genetic tests and the understanding of risk factors can be very difficult and complex. Therefore, genetic counseling will assist individuals in understanding the possible benefits and harms of genetic testing, including the possible impact of the information on the individual's family. Genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing. Genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments. Laboratories that offer laboratory-developed tests must be licensed by the Clinical Laboratory Improvement Amendments for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of these tests.

Table 1 summarizes available targeted treatments with FDA approval for breast cancer (including immunotherapy) and the FDA cleared or approved companion diagnostic tests associated with each. The information in Table 1 was current as of October 16, 2024.. An up-to-date list of FDA cleared or approved companion diagnostics is available at <https://www.fda.gov/medical-devices/in-vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-in-vitro-and-imaging-tools>.

Table 1. Targeted Treatments For Metastatic Breast Cancer And FDA Approved Companion Diagnostic Tests

Treatment	Class	Indications in Breast Cancer	Companion Diagnostic	Pivotal Studies	NCCN Breast Cancer Guideline (V5.2024) Recommendation Level <u>25</u> .
Abemaciclib (Verzenio)a	Cyclin-dependent kinase (CDK) 4/6 inhibitor	• In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with HR-positive, HER2-negative, node-positive, early breast cancer at high risk of recurrence. • In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative advanced or metastatic breast cancer. • In combination with fulvestrant for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. • As monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.	Ki-67 IHC MIB-1 pharmDx (Dako Omnis)	Adjuvant therapy: monarchE (NCT03155997) <u>26,27</u> . Initial endocrine-based therapy for advanced or metastatic disease: MONARCH 3 (NCT02246621) <u>28</u> . With fulvestrant for progressive advanced or metastatic disease: MONARCH 2 (NCT02107703) <u>29,30</u> . Monotherapy for progressive advanced or metastatic disease: MONARCH 1 (NCT02102490) <u>31</u> .	Adjuvant therapy: 1 (Ki-67 testing is not required - see footnotea) Initial endocrine-based therapy for advanced or metastatic disease: 1 (in combination with fulvestrant), 2A (in combination with aromatase inhibitor) With fulvestrant for progressive advanced or metastatic disease: 1 Monotherapy for progressive advanced or metastatic disease: 2A
Ado-trastuzumab emtansine (Kadcyla)b	HER2-targeted antibody and microtubule inhibitor conjugate	As a single agent, for: • Treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in	FoundationOne CDx HER2 FISH pharmDx Kit HercepTest INFORM HER2 Dual ISH DNA Probe Cocktail	Metastatic disease: EMILIA (NCT00829166) <u>32</u> . Adjuvant therapy: KATHERINE (NCT01772472) <u>33</u> .	Metastatic disease: 2A Adjuvant therapy: 1

		combination. Patients should have either: - received prior therapy for metastatic disease, or - developed disease recurrence during or within 6 months of completing adjuvant therapy. - Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment.	PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody		
Alpelisib (Piqray)	Kinase inhibitor	In combination with fulvestrant for the treatment of postmenopausal women, and men, with HR positive, HER2 - negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA approved test following progression on or after an endocrine-based regimen	FoundationOne CDx FoundationOne Liquid CDx therascreen PIK3CA RGQ PCR Kit	SOLAR-1 (NCT02437318) 34 .	1
Dabrafenib (Tafinlar) + Trametinib (Mekinist)	Kinase inhibitors	Adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options	No FDA approved companion diagnostic	ROAR (NCT02034110) 35 . NCI-MATCH arm H (NCT02465060) 36 .	N/A
Dostarlimab-gxly (Jemperli)c	PD-1 blocking antibody	Adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that has progressed on or following prior treatment and who have no satisfactory alternative treatment options	VENTANA MMR Rx Dx Panel	GARNET (NCT02715284) 37 .	2A
Elacestrant (Orserdu)	ER antagonist/SERD	Postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least 1 line of endocrine therapy	Guardant360 CDx	EMERALD (NCT03778931) 38 .	2A
Entrectinib (Rozlytrek)	Kinase inhibitor	Adult and pediatric patients 12 years of age and older with solid tumors that: - have an NTRK gene fusion without a known acquired resistance mutation, - are metastatic or where surgical resection is likely to result in severe morbidity, and - have progressed following treatment or have no satisfactory alternative therapy	FoundationOne CDx (Foundation Medicine, Inc.) FoundationOne Liquid CDx (Foundation Medicine, Inc.)	ALKA (EudraCT 2012-000148-88), STARTRK-1 (NCT02097810), and STARTRK-2 (NCT02568267) 39 .	2A

Fam-trastuzumab deruxtecan-nxki (Enhertu) d	HER-2 targeted antibody and topoisomerase inhibitor conjugate	- Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within 6 months of completing therapy - Adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy	PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody	HER2-positive metastatic disease: DESTINY-Breast03 (NCT03529110)<u>40</u>, HER2-low metastatic disease: DESTINY-Breast04 (NCT03734029)<u>41</u>,	1
Larotrectinib (Vitrakvi)	Kinase inhibitor	Adult and pediatric patients 12 years of age and older with solid tumors that: - have an NTRK gene fusion without a known acquired resistance mutation, - are metastatic or where surgical resection is likely to result in severe morbidity, and - have progressed following treatment or have no satisfactory alternative therapy	FoundationOne CDx	LOXO-TRK-14001 (NCT02122913), SCOUT (NCT02637687), and NAVIGATE (NCT02576431)<u>42</u>,	2A

Olaparib (Lynparza)	PARP inhibitor	- Adjuvant treatment of adults with deleterious or suspected deleterious germline BRCA mutated, HER2-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy - Treatment of adults with deleterious or suspected deleterious germline BRCA mutated, HER-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with HR-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy.	BRCAAnalysis CDx FoundationOne CDx	Adjuvant therapy: OlympiA (NCT02032823) <u>43</u> , Metastatic disease: OlympiAD (NCT02000622) <u>44</u> ,	Adjuvant therapy: 2A Metastatic disease: 1
Pembrolizumab (Keytruda)c	PD-L1-blocking antibody	- Neoadjuvant treatment of high-risk, early-stage TNBC in combination with chemotherapy, then continued as a single agent as adjuvant therapy - In combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 as determined by an FDA approved test	PD-L1 IHC 22C3 pharmDx	Neoadjuvant/adjuvant therapy: KEYNOTE-522 (NCT03036488) <u>45</u> , Unresectable/metastatic disease: KEYNOTE-355 (NCT02819518) <u>46</u> ,	Neoadjuvant/adjuvant therapy: 2A Unresectable/metastatic disease: 1
		Adult and pediatric patients with unresectable or metastatic, microsatellite instability-high or mismatch repair deficient solid tumors that have progressed following prior treatment and who have no satisfactory alternative treatment options	FoundationOne CDx	KEYNOTE-158 (NCT02628067) <u>47</u> ,	2A
		Adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (≥ 10 mutations/megabase) solid tumors, as determined by an FDA approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options.	FoundationOne CDx (Solid tumors TMB $\geq$ 10 mutations per megabase)	KEYNOTE-158 (NCT02628067) <u>48</u> ,	2A
Pertuzumab (Perjeta) e	HER2/neu receptor antagonist	Use in combination with trastuzumab and docetaxel for treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.	HER2 FISH pharmDx Kit HercepTest FoundationOne CDx	Metastatic disease: CLEOPATRA (NCT00567190) <u>49</u> , Neoadjuvant therapy: NeoSphere (NCT00545688) <u>50</u> ,	Metastatic disease: 1 Neoadjuvant/adjuvant therapy: 1 or 2A (regimen-specific)

		Use in combination with trastuzumab and chemotherapy as: • Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. • Adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence		Adjuvant therapy: APHINITY (NCT01358877)<u>51</u>.	
Selpercatinib (Retevmo)	Kinase inhibitor	Adult patients with locally advanced or metastatic solid tumors with a RET gene fusion that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options	No FDA-approved companion diagnostic test	LIBRETTO-001 (NCT03157128) <u>52</u> .	2A
Talazoparib (Talzenna)	PARP inhibitor	Adult patients with deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer	BRACAnalysis CDx	EMBRACA (NCT01945775) <u>53</u> .	1
Trastuzumab (Herceptin) f	HER2/neu receptor antagonist	• Adjuvant treatment of HER2-overexpressing node-positive or node-negative (HR-negative or with 1 high-risk feature) breast cancer as part of a regimen consisting of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel; as part of a regimen with docetaxel and carboplatin; or as a single agent following multi-modality anthracycline-based therapy • Treatment of metastatic HER2-overexpressing breast cancer in combination with paclitaxel (first-line treatment) or as a single agent (after 1 or more chemotherapy regimens for metastatic disease)	Bond Oracle HER2 IHC System FoundationOne CDx HER2 CISH pharmDx Kit HER2 FISH pharmDx Kit HercepTest INFORM HER-2/neu INFORM HER2 Dual ISH DNA Probe Cocktail InSite Her-2/neu KIT PathVysion HER-2 DNA Probe Kit PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody SPOT-LIGHT HER2 CISH Kit VENTANA HER2 Dual ISH DNA Probe Cocktail	Adjuvant therapy: BCIRG-006 (NCT00021255)<u>54</u>. Metastatic disease: CLEOPATRA (NCT00567190)<u>49</u>.	Adjuvant therapy: 1 or 2A (regimen-specific) Metastatic disease: 1 or 2A (regimen-specific)
Itovebi (inavolisib)	Kinase inhibitor	Indicated in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected	FoundationOne CDx (Foundation Medicine, Inc.) FoundationOne Liquid CDx (Foundation Medicine, Inc.) therascreen	INAVO120 (NCT04191499) <u>55</u> .	N/A

9/23/26, 9:41 PM

Itiliti Health::Medical Policies

	by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.	PIK3CA RGQ PCR Kit (QIAGEN GmbH)		
a The FDA-approved indication for adjuvant therapy with abemaciclib was expanded in March 2023 and no longer requires Ki-67 testing. NCCN's recommendation for adjuvant abemaciclib use was similarly updated to no longer stipulate Ki-67 testing. b Covered in Policy 5.01.22. c Covered in Policy 2.04.157. d Placement of fam-trastuzumab deruxtecan-nxki (Enhertu) in the reference medical policy library is under current discussion. eCovered in Policy 5.01.20. f Covered in Policy 5.01.12. dMMR: mismatch repair deficient; ER: estrogen receptor; FDA: U.S. Food & Drug Administration; HER2: human epidermal growth factor receptor 2; HR: hormone receptor; MSI-H: microsatellite instability-high; N/A: not applicable;NCCN: National Comprehensive Cancer Network; NTRK: neurotrophic-tropomyosin receptor kinase; PD-1: programmed death receptor-1; PD-L1: programmed death-ligand 1; PIK3CA: phosphatidylinositol 3-kinase catalytic alpha polypeptide; SERD: selective estrogen receptor degrader; TNBC: triple-negative breast cancer Sources: 56,57.				

In August 2021, Genentech voluntarily withdrew accelerated approval of atezolizumab (Tecentriq) for use in patients with PD-L1 positive, triple-negative breast cancer following FDA assessment of confirmatory trial results.

RATIONALE

Summary Of Evidence

For individuals with metastatic or high-risk, early stage HER2-negative breast cancer being considered for systemic therapy (ie, poly(adenosine diphosphate - ribose) polymerase [PARP] inhibitors) who receive genetic testing for a BRCA1 or BRCA2 germline variant, the evidence includes U.S. Food and Drug Administration (FDA)-approved therapeutics with National Comprehensive Cancer Network (NCCN) recommendations of 2A or higher and was not extensively evaluated. The evidence includes the pivotal studies leading to the FDA and National Comprehensive Cancer Network (NCCN) recommendations.

For individuals with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who receive PIK3CA gene testing to select targeted treatment, the evidence includes FDA-approved therapeutics with NCCN recommendations of 2A or higher and was not extensively evaluated. The evidence includes the pivotal studies leading to the FDA and NCCN recommendations.

For individuals with breast cancer who are being considered for abemaciclib therapy who receive Ki-67 testing, the evidence includes a randomized, controlled, open-label trial. Relevant outcomes include overall survival, disease-specific survival, test validity, quality of life, and treatment-related morbidity. Among patients with hormone receptor-positive, HER2-negative, node-positive, early breast cancer with clinical and pathological features consistent with a high risk of recurrence (n=5637), abemaciclib plus endocrine therapy demonstrated superior invasive disease-free survival compared to endocrine therapy alone (hazard ratio [HR] =0.75; p=.01). For the cohort of patients with Ki-67 score of at least 20% (n=2003 [35.5%]), secondary analysis of invasive disease-free survival was also superior for the group receiving abemaciclib (HR=0.626; p=.0042). However, additional analyses showed the abemaciclib benefit was observed regardless of Ki-67 status. There was no clear benefit of abemaciclib on overall survival in either the intention-to-treat (ITT) population or the FDA-indicated population based on preliminary results that were not subject to peer review. Further study is necessary to confirm whether an improved overall survival benefit is observed among patients with Ki-67 'high' versus 'low' status. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with breast cancer who are being considered for selpercatinib therapy who receive REarranged during Transfection (RET) testing, the evidence includes a nonrandomized, basket trial of individuals with solid tumors with a life expectancy of at least 3 months and disease progression on or after previous systemic therapies or who had no satisfactory therapeutic options. Relevant outcomes include overall survival, disease-specific survival, test validity, quality of life, and treatment-related morbidity. Of 45 enrolled individuals, 2 (4%) had a primary breast tumor. The trial reported an overall response rate of 43.9% in the total population and 100% in the breast cancer population (n=2). Corresponding median duration of response was 24.5 months and 17.3 months. There is no FDA-approved companion diagnostic for use with RET fusion-positive solid tumors. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with breast cancer who are being considered for dabrafenib and trametinib therapy who receive BRAF testing, the evidence includes 2 nonrandomized basket trials of individuals with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment

and have no satisfactory alternative treatment options. Relevant outcomes include overall survival, disease-specific survival, test validity, quality of life, and treatment-related morbidity. The NCI Match and BRF117019 trials reported overall response rates ranging from 31% to 69%, largely driven by partial responders. Duration of response, progression-free survival, and overall survival ranged widely and appeared to be dependent on tumor type. Serious and grade 3 or worse adverse events were common, occurring in up to 63% of study participants. No breast cancer patients were included in either trial. There is currently no FDA-approved companion diagnostic test for BRAF mutated solid tumors other than melanoma and non-small-cell lung cancer for use with dabrafenib plus trametinib. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer who receive circulating tumor DNA testing to select targeted treatment, the evidence includes FDA-approved therapeutics with NCCN recommendations of 2A or higher and was not extensively evaluated. The evidence includes the pivotal studies leading to the FDA and NCCN recommendations.

For individuals with metastatic breast cancer who receive circulating tumor cell (CTC) testing to guide treatment decisions, the evidence includes randomized controlled trials (RCTs), observational studies, and systematic reviews. Relevant outcomes include overall survival, disease-specific survival, test validity, quality of life, and treatment-related morbidity. Systematic reviews and meta-analyses have described an association between CTCs and poor prognosis in metastatic breast cancer, but evidence that CTC-driven treatment improves health outcomes is lacking. One RCT found no improvement in overall survival or progression-free survival (PFS) with CTC-driven treatment (early switching to a different chemotherapy regimen) compared to continuing initial therapy. A second RCT found that CTC-driven first-line therapy was noninferior to clinician-driven therapy in previously untreated patients with metastatic breast cancer (hazard ratio for PFS 0.94; 95% confidence interval 0.81 to 1.09). The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals with recurrent unresectable (local or regional) or stage IV breast cancer who receive NTRK gene fusion testing to guide treatment decisions, the evidence includes FDA-approved therapeutics with National Comprehensive Cancer Network (NCCN) recommendations of 2A or higher and was not extensively evaluated. The evidence includes the pivotal studies leading to the FDA and National Comprehensive Cancer Network (NCCN) recommendations.

SUPPLEMENTAL INFORMATION

Practice Guidelines And Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Society Of Clinical Oncology

In 2022, the American Society of Clinical Oncology published an updated guideline on biomarker testing to guide systemic therapy in patients with metastatic breast cancer.⁷² The guideline recommended the following biomarker tests:

- PIK3CA (Type of recommendation: evidence-based; Evidence quality: high; Strength of recommendation: strong)
- Germline BRCA1 and BRCA2 (Type of recommendation: evidence-based; Evidence quality: high; Strength of recommendation: strong)
- PD-L1 (Type of recommendation: evidence-based; Evidence quality: intermediate; Strength of recommendation: strong)
- MSI-H/dMMR (Type of recommendation: informal consensus-based; Evidence quality: low; Strength of recommendation: moderate)
- TMB (Type of recommendation: informal consensus-based; Evidence quality: low; Strength of recommendation: moderate)
- NTRK fusions (Type of recommendation: informal consensus-based; Evidence quality: low; Strength of recommendation: moderate)

The following biomarker tests were not recommended by ASCO: PALB2, TROP2 expression, circulating tumor DNA, circulating tumor cell.

Detailed recommendations are as follows:

- Patients with locally recurrent unresectable or metastatic hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer who are candidates for a treatment regimen that includes a phosphatidylinositol 3-kinase inhibitor and a hormonal therapy should undergo testing for PIK3CA mutations using next-generation sequencing of tumor tissue or circulating tumor DNA (ctDNA) in plasma to determine their eligibility for treatment with the phosphatidylinositol 3-kinase inhibitor alpelisib plus fulvestrant. If no mutation is found in ctDNA, testing in tumor tissue, if available, should be used as this will detect a small number of additional patients with PIK3CA mutations (Type of recommendation: evidence-based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong)
- Patients with metastatic HER2-negative breast cancer who are candidates for treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor should undergo testing for germline BRCA1 and BRCA2 pathogenic or likely pathogenic mutations to determine their eligibility for treatment with the PARP inhibitors olaparib or talazoparib (Type of recommendation: evidence-based, benefits outweigh harms; Evidence quality: high; Strength of recommendation: strong).
- There is insufficient evidence to support a recommendation either for or against testing for a germline PALB2 pathogenic variant for the purpose of determining eligibility for treatment with PARP inhibitor therapy in the metastatic setting. This recommendation is independent of the indication for testing to assess cancer risk (Type: informal consensus; Evidence quality: low; Strength of recommendation: moderate).
 - Small single-arm studies show that oral PARP inhibitor therapy demonstrates high response rates in MBC encoding DNA repair defects, such as germline PALB2 pathogenic variants and somatic BRCA1/2 mutations. It should also be noted that the randomized PARP inhibitor trials made no direct comparison with taxanes, anthracyclines, or platinum; comparative efficacy against these compounds is unknown. There are insufficient data at present to recommend routine testing of tumors for homologous recombination deficiency to guide therapy for MBC (Type: informal consensus; Evidence quality: low; Strength of recommendation: moderate).

- Patients with locally recurrent unresectable or metastatic hormone receptor-negative and HER2-negative breast cancer who are candidates for a treatment regimen that includes an immune checkpoint inhibitor (ICI) should undergo testing for expression of programmed cell death ligand-1 in the tumor and immune cells with a US Food and Drug Administration - approved test to determine eligibility for treatment with the ICI pembrolizumab plus chemotherapy (Type of recommendation: evidence based, benefits outweigh harms; Evidence quality: intermediate; Strength of recommendation: strong).
- Patients with metastatic cancer who are candidates for a treatment regimen that includes an ICI should undergo testing for deficient mismatch repair/microsatellite instability-high to determine eligibility for dostarlimab-gxly or pembrolizumab (Type of recommendation: informal consensus; Evidence quality: low; Strength of recommendation: moderate).
- Patients with metastatic cancer who are candidates for treatment with an ICI should undergo testing for tumor mutational burden to determine eligibility for pembrolizumab monotherapy (Type of recommendation: informal consensus; Evidence quality: low; Strength of recommendation: moderate).
- Clinicians may test for NTRK fusions in patients with metastatic cancer who are candidates for a treatment regimen that includes a TRK inhibitor to determine eligibility for larotrectinib or entrectinib (Type of recommendation: informal consensus; Evidence quality: low; Strength of recommendation: moderate).
- There are insufficient data to recommend routine testing of tumors for TROP2 expression to guide therapy with an anti-TROP2 antibody-drug conjugate for hormone receptor-negative, HER2-negative MBC (Type of recommendation: informal consensus; Evidence quality: low; Strength of recommendation: moderate).
- There are insufficient data to recommend routine use of ctDNA to monitor response to therapy among patients with MBC (Type of recommendation: informal consensus; Evidence quality: low; Strength of recommendation: moderate).
- There are insufficient data to recommend routine use of circulating tumor cells to monitor response to therapy among patients with MBC (Type of recommendation: informal consensus; Evidence quality: low; Strength of recommendation: moderate).

A rapid update to the ASCO guideline was published in March 2023 to address ESR1 testing (which was not recommended in the previous version).⁷³ The guideline recommended routine testing for ESR1 mutations at the time of disease recurrence or progression while receiving endocrine therapy, with or without a concomitant CDK4/6 inhibitor, in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer (Type of recommendation: evidence-based; Evidence quality: high; Strength of recommendation: strong). Testing should be performed with blood or tissue obtained at the time of progression, as ESR1 alterations develop via selective pressure from treatment and are unlikely to be detected in the primary tumor. Blood-based ctDNA is preferred due to greater sensitivity.

National Comprehensive Cancer Network

Table 2 summarizes National Comprehensive Cancer Network guidelines (v. 4.2023) on biomarker testing for the biomarkers included in this policy.²⁵ The guidelines state that the use of circulating tumor cells or circulating tumor DNA in metastatic breast cancer is not yet included in algorithms for disease assessment and monitoring. For patients being considered for treatment with alpelisib, testing for PIK3CA with either tissue or liquid biopsy is recommended (category 1 recommendation). For patients being considered for treatment with elacestrant, testing for ESR1 with liquid biopsy is recommended (category 2A recommendation).

Table 2. National Comprehensive Cancer Network Guidelines On Biomarker Testing For Targeted Treatment Of Breast Cancer

Biomarker	Breast Cancer Subtype	FDA Approved Agents	Testing Recommendation	Targeted Therapy Category of Evidence	Targeted Therapy Category of Preference
BRCA1/2 mutations	Any	Olaparib Talazoparib	Patients with recurrent or metastatic breast cancer should be assessed for BRCA1/2 mutations with germline sequencing to identify candidates for PARP inhibitor therapy. While olaparib and talazoparib are FDA-indicated in HER2-negative disease, NCCN supports use in any breast cancer subtype associated with a germline BRCA1 or BRCA2 mutation.	1	Preferred
PIK3CA	HR-positive/HER2-negative	Alpelisib + fulvestrant	For HR-positive/HER2-negative breast cancer, assess for PIK3CA mutations with tumor or liquid biopsy to identify candidates for alpelisib plus fulvestrant. PIK3CA mutation testing can be done on tumor tissue or ctDNA in peripheral blood (liquid biopsy). If liquid biopsy is negative, tumor tissue testing is recommended.	1	Preferred second-or subsequent-line therapy
ESR1 mutation	HR-positive/HER2-negative	Elacestrant	For postmenopausal females or adult males with ER-positive, HER2-negative, ESR1-mutated disease after progression on one or two prior lines of endocrine therapy, including one line containing a CDK4/6 inhibitor. Blood testing is recommended.	2A	Other recommended regimen

PD-L1 expression (combined positive score ≥10)	Triple negative	Pembrolizumab + chemotherapy (albumin-bound paclitaxel, or gemcitabine and carboplatin)	For triple-negative breast cancer, assess PD-L1 expression using 22C3 antibody via immunohistochemistry. While available data are in the first-line setting, this regimen can be used for second and subsequent lines of therapy if PD-1/PD-L1 inhibitor therapy has not been previously used.	1	Preferred first-line therapy
MSI-H/dMMR	Any	Pembrolizumab Dostarlimab-gxly	Biomarker detection via immunohistochemistry or PCR tissue block is recommended. If a patient with unresectable or metastatic MSI-H/dMMR breast cancer has progressed on or following prior treatment with no satisfactory alternative treatment options, pembrolizumab or dostarlimab-gxly are indicated.	2A	Useful in certain circumstances
TMB-H (≥10 mut/mb)	Any	Pembrolizumab	Biomarker detection via NGS is indicated in patients with unresectable or metastatic TMB-H tumors that have progressed following prior treatment and who have no satisfactory treatment options.	2A	Useful in certain circumstances
RET-fusion	Any	Selpercatinib	Biomarker detection via NGS is recommended in adult patients with locally advanced or metastatic solid tumors that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.	2A	Useful in certain circumstances

Source: Adapted from National Comprehensive Cancer Network guidelines on Breast Cancer (v. 5.2024)[25](#).

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

In January 2020, the Centers for Medicare and Medicaid Services (CMS) determined that next-generation sequencing (NGS) is covered for patients with breast or ovarian cancer when the diagnostic test is performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory AND the test has approval or clearance by the U.S. Food and Drug Administration (CAG-00450R).[74](#).

CMS states that local Medicare carriers may determine coverage of NGS for management of the patient for any cancer diagnosis with a clinical indication and risk factor for germline testing of hereditary cancers when performed in a CLIA-certified laboratory.

CODES		
Codes	Number	Description
ICD10-CM	C50.011-C50.929	Malignant neoplasm of the breast code range
	C79.81	Secondary malignant neoplasm of breast

CURRENT CODING

CPT:

Code	Description	Line of Business
0022U	DNA and RNA targeted sequencing analysis of 1-23 genes associated with non-small cell lung cancer, reported as presence/absence of variants and associated therapies to consider	FEP
0023U	DNA gene analysis for acute myelogenous leukemia	FEP
0037U	DNA gene analysis of 324 genes in solid organ tumor tissue	FEP
0040U	Gene analysis (t(9;22)) for translocation analysis	FEP
0111U	Gene analysis (KRAS and NRAS) in prostate tumor tissue	FEP
0154U	RNA gene analysis for detection of fibroblast growth factor receptor 3 gene alteration in urothelial tumor tissue specimen	FEP
0155U	DNA analysis for detection of PIK3CA gene mutation in breast growth tissue specimen	FEP
0172U	DNA gene analysis (BRCA1, DNA repair associated and BRCA2, DNA repair associated) for detection of mutations associated with breast cancer	FEP
0177U	DNA gene analysis (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) for detection of mutations associated with breast cancer	FEP
0211U	Next-generation sequencing of DNA and RNA in tumor tissue specimen with interpretative report	FEP
0239U	Gene analysis of 311 or more genes associated with solid organ cancer in cell-free DNA, targeted sequence panel	FEP
0326U	Targeted genomic sequence analysis of 83 or more genes in cell free circulating DNA for detection of abnormalities associated with solid organ cancers	FEP
0338U	Evaluation of circulating solid tumor cells in peripheral blood	FEP
0471U	Testing for 35 variants of KRAS and NRAS genes in tissue sample, reported as predictive identification of detected mutations in colorectal cancer	FEP
0473U	Next-generation sequencing of DNA from tissue sample of 648 genes with comparative sequence analysis from a matched normal blood or saliva specimen in solid tumor cancer	FEP
0523U	DNA next generation sequencing of 22 genes in solid tumor cancers	FEP
0543U	DNA next-generation sequencing of 517 genes in solid tumor cancers	FEP
81120	Gene analysis (isocitrate dehydrogenase 1 [NADP+], soluble) for common variants	FEP
81121	Gene analysis (isocitrate dehydrogenase 2 [NADP+], mitochondrial) for common variants	FEP
81162	Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion variants	FEP
81163	Gene analysis (breast cancer 1 and 2) of full sequence	FEP
81164	Gene analysis (breast cancer 1 and 2) for duplication or deletion variants	FEP
81165	Gene analysis (breast cancer 1) of full sequence	FEP
81167	Gene analysis (breast cancer 2) for duplication or deletion variants	FEP
81191	Gene analysis (neurotrophic receptor tyrosine kinase 1) translocation analysis	FEP

Code	Description	Line of Business
81192	Gene analysis (neurotrophic receptor tyrosine kinase 2) translocation analysis	FEP
81193	Gene analysis (neurotrophic receptor tyrosine kinase 3) translocation analysis	FEP
81194	Gene analysis (neurotrophic receptor tyrosine kinase 1, 2, and 3) translocation analysis	FEP
81206	Translocation analysis (BCR/ABL1) major breakpoint	FEP
81207	Translocation analysis (BCR/ABL1) minor breakpoint	FEP
81210	Gene analysis (v-raf murine sarcoma viral oncogene homolog B1)	FEP
81212	Gene analysis (breast cancer 1 and 2) for 185delAG, 5385insC, 6174delT variants	FEP
81215	Gene analysis (breast cancer 1) for known familial variant	FEP
81217	Gene analysis (breast cancer 2) for known familial variant	FEP
81235	Gene analysis (epidermal growth factor receptor), common variants	FEP
81236	Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) of full sequence	FEP
81237	Gene analysis (enhancer of zeste 2 polycomb repressive complex 2 subunit) for common variants	FEP
81245	Gene analysis (fms-related tyrosine kinase 3) internal tandem duplication variants	FEP
81246	Test for detecting genes associated with blood cancer	FEP
81272	Gene analysis (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), targeted sequence	FEP
81273	Gene analysis (v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog), D816 variants	FEP
81275	Gene analysis (v-Ki-ras2 Kirsten rat sarcoma viral oncogene) variants in codons 12 and 13	FEP
81276	Gene analysis (Kirsten rat sarcoma viral oncogene homolog), additional variants	FEP
81301	Microsatellite instability analysis	FEP
81307	Gene analysis (partner and localizer of BRCA2) full sequence analysis	FEP
81308	Gene analysis (partner and localizer of BRCA2) for detection of known familial variant	FEP
81309	Gene analysis (partner and localizer of BRCA2) targeted sequence analysis	FEP
81311	Gene analysis for cancer (neuroblastoma)	FEP
81314	Gene analysis ((platelet-derived growth factor receptor, alpha polypeptide) targeted sequence	FEP
81351	Gene analysis (tumor protein 53) full sequence analysis	FEP
81352	Gene analysis (tumor protein 53) targeted sequence analysis	FEP
81353	Gene analysis (tumor protein 53) targeted sequence analysis for detection of known familial variant	FEP
81370	HLA class I and II typing low resolution HLA-A, -B, -C, -DRB1/3/4/5 and -DQB1	FEP
81371	HLA class I and II typing, low resolution HLA-A, -B, and -DRB1	FEP

Code	Description	Line of Business
81372	HLA class I typing low resolution	FEP
81373	HLA class I typing low resolution one locus	FEP
81374	HLA class I typing, low resolution one antigen equivalent	FEP
81375	HLA class II typing low resolution HLA-DRB1/3/4/5 and -DQB1	FEP
81376	HLA class II typing low resolution one locus	FEP
81377	HLA class II typing low resolution one antigen equivalent	FEP
81378	HLA class I and II typing high resolution HLA-A, -B, -C, and -DRB1	FEP
81379	HLA Class I typing high resolution	FEP
81380	HLA class I typing high resolution one locus	FEP
81381	HLA class I typing high resolution one allele or allele group	FEP
81382	HLA class II typing high resolution one locus	FEP
81383	HLA class II typing high resolution one allele or allele group	FEP
81400	Molecular pathology procedure level 1	FEP
81401	Molecular pathology procedure level 2	FEP
81402	Molecular pathology procedure level 3	FEP
81403	Molecular pathology procedure level 4 genetic analysis	FEP
81404	Molecular pathology procedure level 5 genetic analysis	FEP
81405	Molecular pathology procedure level 6 genetic analysis	FEP
81406	Molecular pathology procedure level 7 genetic analysis	FEP
81407	Molecular pathology procedure level 8 genetic analysis	FEP
81408	Molecular pathology procedure level 9 genetic analysis	FEP
81432	Test for detecting genes associated with inherited breast cancer-related disorders, genomic sequence analysis, at least 5 genes	FEP
81445	Genomic sequence analysis panel of DNA or combined DNA and RNA of 5-50 genes associated with solid organ abnormal growth of tissue	FEP
81449	Genomic sequence analysis panel of RNA of 5-50 genes associated with solid organ abnormal growth of tissue	FEP
81450	Genomic sequence analysis panel of DNA or combined DNA and RNA of 5-50 genes associated with blood and lymphatic system disorders	FEP
81455	Genomic sequence analysis panel of DNA or combined DNA and RNA of 51 or more genes associated with blood and lymphatic system disorders	FEP
81456	Genomic sequence analysis panel of RNA of 51 or more genes associated with blood and lymphatic system disorders	FEP
81479	Molecular pathology procedure	FEP
88271	DNA testing for genetic defects	FEP
88275	Chromosome analysis for genetic defects, analyze 100-300 cells	FEP
88341	Special stained specimen slides to examine tissue, each additional procedure	FEP
88342	Special stained specimen slides to examine tissue, initial procedure	FEP
88360	Microscopic genetic analysis of tumor, manual	FEP

Code	Description	Line of Business
88361	Microscopic genetic analysis of tumor, using computer-assisted technology	FEP
88364	Genetic sequencing localization, each additional procedure	FEP
88365	Genetic sequencing localization, initial procedure	FEP
88366	Genetic sequencing localization, each multiplex procedure	FEP
88367	Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure	FEP
88368	Microscopic genetic analysis of tissue, manual, initial procedure	FEP
88369	Microscopic genetic analysis of tissue, manual, each additional procedure	FEP
88374	Microscopic genetic analysis of tissue, computer-assisted technology, initial procedure, each multiplex procedure	FEP
88377	Microscopic genetic analysis of tissue, manual, each additional multiplex stain procedure	FEP
96041	Counseling for genetic testing provided by a genetic counselor, each 30 minutes of total time on the date of encounter	FEP

REFERENCES

- Wang L, Lu Q, Jiang K, et al. BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review. *Oncol Res Treat*. 2022; 45(1-2): 54-61. PMID 34818649
- Albanell J, Elvin JA, Suh J, et al. BRAF Genetic Alterations in Breast Cancer. *Ann Oncol*. October 1 2016; 27(Supp 6): v170.
- Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step toward manageable disease. *Clin Cancer Res*. Apr 01 2011; 17(7): 1658-63. PMID 21447722
- Dummer R, Goldinger SM, Turtshi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. *Eur J Cancer*. Feb 2014; 50(3): 611-21. PMID 24295639
- Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *Lancet Oncol*. Nov 2012; 13(11): 1087-95. PMID 23051966
- Thunnissen E, van der Oord K, den Bakker M. Prognostic and predictive biomarkers in lung cancer. A review. *Virchows Arch*. Mar 2014; 464(3): 347-58. PMID 24420742
- Nelson HD, Pappas M, Cantor A, et al. Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. *JAMA*. Aug 20 2019; 322(7): 666-685. PMID 31429902
- Hemel D, Domchek SM. Breast cancer predisposition syndromes. *Hematol Oncol Clin North Am*. Oct 2010; 24(5): 799-814. PMID 20816575
- Yoshida R. Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis. *Breast Cancer*. Nov 2021; 28(6): 1167-1180. PMID 32862296
- Winchester DP. Breast cancer in young women. *Surg Clin North Am*. Apr 1996; 76(2): 279-87. PMID 8610264
- Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. *J Clin Oncol*. Mar 15 2002; 20(6): 1480-90. PMID 11896095
- Langston AA, Malone KE, Thompson JD, et al. BRCA1 mutations in a population-based sample of young women with breast cancer. *N Engl J Med*. Jan 18 1996; 334(3): 137-42. PMID 8531967
- Malone KE, Daling JR, Thompson JD, et al. BRCA1 mutations and breast cancer in the general population: analyses in women before age 35 years and in women before age 45 years with first-degree family history. *JAMA*. Mar 25 1998; 279(12): 922-9. PMID 9544766
- Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. *Am J Hum Genet*. Mar 1998; 62(3): 676-89. PMID 9497246
- Gershoni-Baruch R, Patael Y, Dagan A, et al. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. *Br J Cancer*. Jul 2000; 83(2): 153-5. PMID 10901363
- Warner E, Foulkes W, Goodwin P, et al. Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. *J Natl Cancer Inst*. Jul 21 1999; 91(14): 1241-7. PMID 10413426
- Hartge P, Struwing JP, Wacholder S, et al. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. *Am J Hum Genet*. Apr 1999; 64(4): 963-70. PMID 10090881
- Hodgson SV, Heap E, Cameron J, et al. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. *J Med Genet*. May 1999; 36(5): 369-73. PMID 10353781
- de Ruijter TC, Veeck J, de Hoon JP, et al. Characteristics of triple-negative breast cancer. *J Cancer Res Clin Oncol*. Feb 2011; 137(2): 183-92. PMID 21069385
- Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. *BMC Cancer*. Mar 19 2009; 9: 86. PMID 19298662
- Gonzalez-Angulo AM, Timms KM, Liu S, et al. Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer. *Clin Cancer Res*. Mar 01 2011; 17(5): 1082-9. PMID 21233401

22. Cao W, Xing H, Li Y, et al. Claudin18.2 is a novel molecular biomarker for tumor-targeted immunotherapy. *Biomark Res.* May 31 2022; 10(1): 38. PMID 35642043
23. Huang Y, Ye Y, Yi T, et al. CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma. *Front Pharmacol.* 2025; 16: 1559558. PMID 40206086
24. Tojjari A, Idrissi YA, Saeed A. Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2. *Cancer Lett.* Dec 03 2024; 611: 217362. PMID 39637967
25. Fang W, Zhang J, Liang W, et al. Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. *J Thorac Dis.* Oct 2013; 5(5): 585-92. PMID 24255770
26. Mitsudomi T, Kosaka T, Yatabe Y. Biological and clinical implications of EGFR mutations in lung cancer. *Int J Clin Oncol.* Jun 2006; 11(3): 190-8. PMID 16850125
27. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. *J Clin Oncol.* Sep 01 2005; 23(25): 5900-9. PMID 16043828
28. Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. *N Engl J Med.* Sep 03 2009; 361(10): 958-67. PMID 19692684
29. Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. *Clin Cancer Res.* Apr 15 2013; 19(8): 2240-7. PMID 23470965
30. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. *Sci Transl Med.* Mar 23 2011; 3(75): 75ra26. PMID 21430269
31. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. *Nat Genet.* Dec 2013; 45(12): 1439-45. PMID 24185512
32. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor- α mutations in pretreated advanced estrogen receptor-positive breast cancer. *Clin Cancer Res.* Apr 01 2014; 20(7): 1757-1767. PMID 24398047
33. Duan R, Du W, Guo W. EZH2: a novel target for cancer treatment. *J Hematol Oncol.* Jul 28 2020; 13(1): 104. PMID 32723346
34. Romero P, Richart L, Aflaki S, et al. EZH2 mutations in follicular lymphoma distort H3K27me3 profiles and alter transcriptional responses to PRC2 inhibition. *Nat Commun.* Apr 24 2024; 15(1): 3452. PMID 38658543
35. Seraji N, Berger I. FGFR as a Predictive Marker for Targeted Therapy in Gastrointestinal Malignancies: A Systematic Review. *J Gastrointest Cancer.* Apr 09 2025; 56(1): 96. PMID 40205008
36. Zhang P, Yue L, Leng Q, et al. Targeting FGFR for cancer therapy. *J Hematol Oncol.* Jun 03 2024; 17(1): 39. PMID 38831455
37. Du S, Zhang Y, Xu J. Current progress in cancer treatment by targeting FGFR signaling. *Cancer Biol Med.* Jul 24 2023; 20(7): 490-9. PMID 37493315
38. Fedorov K, Maiti A, Konopleva M. Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. *Cancers (Basel).* Apr 15 2023; 15(8). PMID 37190240
39. Rataj J, Gorecki L, Muthna D, et al. Targeting FMS-like tyrosine kinase 3 (FLT3) in acute myeloid leukemia: Novel molecular approaches and therapeutic challenges. *Biomed Pharmacother.* Jan 2025; 182: 117788. PMID 39733588
40. Tamburini J, Mouche S, Larrue C, et al. Very short insertions in the FLT3 gene are of therapeutic significance in acute myeloid leukemia. *Blood Adv.* Dec 26 2023; 7(24): 7576-7580. PMID 37987760
41. Mai J, Wu L, Yang L, et al. Therapeutic strategies targeting folate receptor α for ovarian cancer. *Front Immunol.* 2023; 14: 1254532. PMID 37711615
42. National Cancer Institute. NCI Dictionaries: Homologous Recombination Repair Pathway. n.d. <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/homologous-recombination-repair-pathway>. Accessed May 15, 2026.
43. Mateo J, Boysen G, Barbieri CE, et al. DNA Repair in Prostate Cancer: Biology and Clinical Implications. *Eur Urol.* Mar 2017; 71(3): 417-425. PMID 27590317
44. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Prostate Cancer. v5.2026. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf Accessed May 30, 2026.
45. Myriad Genetics. MyChoice CDx Myriad HRD Companion Diagnostic Test. 2024. <https://myriad.com/genetic-tests/mychoicecdx-tumor-test/>. Accessed May 15, 2026.
46. Tew WP, Lacchetti C, Kohn EC. Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update. *J Clin Oncol.* Nov 20 2022; 40(33): 3878-3881. PMID 36150092
47. Singh H, Kang A, Bloudek L, et al. Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer. *JNCI Cancer Spectr.* Jan 04 2024; 8(1). PMID 37815820
48. Wang, C., Xiong, C., Hsu, Y., Wang, X., & Chen, L. (2020). Human leukocyte antigen (HLA) and cancer immunotherapy: HLA-dependent and -independent adoptive immunotherapies. *Annals Of Blood*, 5. doi:10.21037/aob-20-27
49. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Adult Glioma. v1.2026. https://www.nccn.org/professionals/physician_gls/pdf/cns.pdf. Accessed May 21, 2026.
50. Heinrich MC, Blanke CD, Corless CL, et al. KIT as a Therapeutic Target. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. *Holland-Frei Cancer Medicine*. 6th edition. Hamilton (ON): BC Decker; 2003. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK13813/>
51. Testa U, Pelosi E, Castelli G. Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic Developments. *Cancers (Basel).* Apr 23 2026; 18(9). PMID 42122138
52. Bonneville R, Krook MA, Chen HZ, et al. Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing. *Methods Mol Biol.* 2020; 2055: 119-132. PMID 31502149
53. TRK Fusion Cancer (Testing). <https://trkcancer.com/testing>. Accessed May 17, 2026.
54. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. *Br J Cancer.* Feb 27 2006; 94(4): 455-9. PMID 16449998
55. Sun Y, Yue L, Xu P, et al. An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors. *Front Oncol.* 2022; 12: 927587. PMID 36119525
56. Ondrejka SL, Jegalian AG, Kim AS, et al. PDGFRB-rearranged T-lymphoblastic leukemia/lymphoma occurring with myeloid neoplasms: the missing link supporting a stem cell origin. *Haematologica.* Sep 2014; 99(9): e148-51. PMID 24951465
57. Regua AT, Najjar M, Lo HW. RET signaling pathway and RET inhibitors in human cancer. *Front Oncol.* 2022; 12: 932353. PMID 35957881
58. Nagasaka M, Brazel D, Baca Y, et al. Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset. *Transl Oncol.* Oct 2023; 36: 101744. PMID 37516008
59. Santoro M, Moccia M, Federico G, et al. RET Gene Fusions in Malignancies of the Thyroid and Other Tissues. *Genes (Basel).* Apr 15 2020; 11(4). PMID 32326537

9/23/26, 9:41 PM

Itiliti Health::Medical Policies

60. Merino DM, McShane LM, Fabrizio D, et al. Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. J Immunother Cancer. Mar 2020; 8(1). PMID 32217756

61. Wang H, Guo M, Wei H, et al. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. Mar 01 2023; 8(1): 92. PMID 36859359

62. Nishikawa S, Iwakuma T. Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials. Cancers (Basel). Jan 09 2023; 15(2). PMID 36672377

63. U.S. Food & Drug Administration. List of Cleared or Approved Companion Diagnostic Devices (In Vitro and Imaging Tools). <https://www.fda.gov/medical-devices/vitro-diagnostics/list-cleared-or-approved-companion-diagnostic-devices-vitro-and-imaging-tools>. Accessed May 16, 2026.

64. U.S. Food & Drug Administration. Drugs@FDA: FDA-Approved Drugs. <https://www.accessdata.fda.gov/scripts/cder/daf/>. Accessed May 15, 2026.

65. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. Jan 2009; 45(2): 228-47. PMID 19097774

66. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. Apr 10 2010; 28(11): 1963-72. PMID 20231676

67. Chakravarty D, Johnson A, Sklar J, et al. Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion. J Clin Oncol. Apr 10 2022; 40(11): 1231-1258. PMID 35175857

68. Burstein HJ, DeMichele A, Somerfield MR, et al. Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. Jun 20 2023; 41(18): 3423-3425. PMID 37196213

69. Lowrance W, Dreicer R, Jarrard DF, et al. Updates to Advanced Prostate Cancer: AUA/SUO Guideline (2023). J Urol. Jun 2023; 209(6): 1082-1090. PMID 37096583

70. Centers for Medicare and Medicaid Services (CMS). Decision Memo: Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer [CAG-00450R]. January 2020; <https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=296>. Accessed May 17, 2026.

71. Centers for Medicare & Medicaid Services. 2020. National Coverage Determination 90.2: Next Generation Sequencing. <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=372&ncdver=2&NCAId=296&bc=ACAAAAACAAA&>. Accessed May 15, 2026.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP®
PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO
THE HISTORY BELOW:

Date	Action	Description
March 2021	New policy	Policy created with literature review on November 20, 2020. Policy statements included for: testing for PIK3CA, NTRK Gene Fusions, PD-L1, MSI-H/dMMR, Tumor Mutational Burden, Circulating Tumor DNA, and Circulating Tumor Cells.
March 2022	Replace policy	Policy updated with literature review through November 8, 2021; references added. Investigational policy statements added for MSI-H/dMMR testing for dostarlimab-gxly, and PD-L1 testing for atezolizumab. Medically necessary policy statements and rationale for BRCA1/2 testing to predict treatment response to PARP inhibitors were migrated into this policy from evidence review 2.04.02. Medically necessary policy statement added for Ki-67 testing for abemaciclib to correlate with FEP pharmacy policy 5.20.104. Policy title updated to reflect both germline and somatic biomarker testing.
March 2023	Replace policy	Policy updated with literature review through October 24, 2022; references added. Evidence on the use of atezolizumab in individuals with triple negative PD-L1 positive breast cancer removed from policy, as in 2021 Genentech voluntarily withdrew accelerated approval of atezolizumab for use in these individuals.
March 2024	Replace policy	Policy updated with literature review through October 25, 2023; references added. Evidence review extensively pruned. Evidence on PD-L1, MSI-H/dMMR, and tumor mutational burden testing for immunotherapy removed as it is covered in evidence review 2.04.157. Pivotal studies and NCCN recommendations added to Table 1. Minor editorial change to PIK3CA policy statement; intent unchanged. Liquid biopsy testing for ESR1 incorporated into circulating tumor DNA indication, with corresponding updates to policy statements and guidelines. Other policy statements unchanged. Language added to policy guidelines to clarify that HER2 testing is not addressed in this review. Policy title and objective updated to reflect that only testing for targeted therapy is reviewed.
March 2025	Replace policy	Policy updated with literature review through November 1, 2024; references added. Title changed to include NTRK. Medically necessary policy statement added for NTRK gene fusion testing for individuals with recurrent unresectable (local or regional) or stage IV breast cancer to select individuals for treatment with FDA-approved therapies. Investigational policy statement added for NTRK gene fusion testing in all other situations. All other policy statements unchanged.
July 2026	Replace policy	81406 in coding twice.
September 2026	Replace policy	Policy updated with literature review through May 15, 2026; Table 1 updated with new entries. Title changed to exclude the word biomarkers. Medically necessary policy statement added for KMT2A gene rearrangement variant testing for individuals with relapsed or refractory acute leukemia to select individuals for treatment with FDA-approved therapies. Policy statement regarding KIT D816V was revised for clarity but intent was not changed. Other policy statements unchanged.

Date	Action	Description
October 2026	Replace policy	Add 0111U

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.

Plans that elect to use the BCBSA reference medical policies as their Plan medical policies should ensure that all internal and external communications clearly reflect that it is the Plan, and not BCBSA, that makes the Plan's policy decisions, and the Plan must place the contents of the reference medical policy on their respective Plan medical policy template. When a Plan elects to adopt any or all of the reference medical policies, the Plan makes an independent decision regarding medical policies and is fully responsible for that decision.